Merck & Co Archives -

Trial answers the KRAS question for Keytruda in lung cancer

https://pharmaphorum.com/news/trial-answers-the-kras-question-for-keytruda-in-lung-cancer/

AZ’s Imfinzi approved in early lung cancer in China

https://pharmaphorum.com/news/azs-imfinzi-approved-in-early-lung-cancer-in-china/

Merck buys ArQule and BTK drug for $2.7bn

https://pharmaphorum.com/news/merck-buys-arqule-for/

Scotland backs AZ’s Lynparza for first-line ovarian cancer maintenance

https://pharmaphorum.com/news/scotland-backs-azs-lynparza-for-first-line-ovarian-cancer-maintenance/

Roche steps up Merck challenge with first-line NSCLC approval in US

https://pharmaphorum.com/news/roche-continues-merck-challenge-with-first-line-nsclc-approval-in-us/

FDA sets January action date for Keytruda in early bladder cancer

https://pharmaphorum.com/news/fda-sets-january-action-date-for-keytruda-in-early-bladder-cancer/

Pharma and Biotech IP 2020

https://pharmaphorum.com/events/pharma-biotech-ip-2020/

Merck & Co’s Keytruda shows promise with prostate cancer ‘super responders’

https://pharmaphorum.com/news/merck-cos-keytruda-shows-promise-with-prostate-cancer-super-responders/

Merck/Bayer set to challenge Novartis in heart failure after phase 3 trial success

https://pharmaphorum.com/news/merck-bayers-heart-failure-drug-on-target-at-phase-3/

Search